Combination IL-2 immunoconjugate therapy

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 10603360
APP PUB NO 20170056522A1
SERIAL NO

15353587

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ROCHE GLYCART AGWAGISTRASSE 18 SCHLIEREN CH-8952

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Gerdes, Christian Erlenbach, CH 18 210
Klein, Christian Bonstetten, CH 571 9941
Nicolini, Valeria G Erlenbach, CH 31 478
Umana, Pablo Wollerau, CH 247 5409

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 30, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 30, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00